MMP13 is a critical target gene during the progression of osteoarthritis

Arthritis Research and Therapy

Volumn 15, Issue 1, 2013, Pages

  Wang, Meina ^a,b   Sampson, Erik R ^a,c   Jin, Hongting ^a,d   Li, Jia ^e,f   Ke, Qiao H ^e   Im, Hee Jeong ^e   Chen, Di ^a,e  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ABBOTT LABORATORIES   (United States)

^d ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f LIAONING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; CL 82198; COLLAGEN TYPE 2; COLLAGENASE 3; MATRIX METALLOPROTEINASE INHIBITOR; PROTEOGLYCAN; TAMOXIFEN; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; MMP13 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARTILAGE; CARTILAGE CELL; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KNEE OSTEOARTHRITIS; MORPHOMETRICS; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; TIBIA; WILD TYPE; ANIMAL; C57BL MOUSE; DISEASE MODEL; ENZYMOLOGY; GENETICS; METABOLISM; MUTANT MOUSE STRAIN; OSTEOARTHRITIS; PATHOLOGY; TUNEL ASSAY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MATRIX METALLOPROTEINASE 13; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; OSTEOARTHRITIS;

EID: 84871974005     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4133     Document Type: Article

References (28)

1. Goldring MB, Goldring SR. Osteoarthritis. J Cell Physiol 2007, 213:626-634. 10.1002/jcp.21258, 17786965.
2. Wang M, Shen J, Jin H, Im HJ, Sandy J, Chen D. Recent progress in understanding molecular mechanisms of cartilage degeneration during osteoarthritis. Ann N Y Acad Sci 2011, 1240:61-69. 10.1111/j.1749-6632.2011.06258.x, 22172041.
3. Vincenti MP, Brinckerhoff CE. Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res 2002, 4:157-164. 10.1186/ar401, 128926, 12010565.
4. Shiomi T, Lemaître V, D'Armiento J, Okada Y. Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases. Pathol Int 2010, 60:477-496. 10.1111/j.1440-1827.2010.02547.x, 20594269.
5. Roach HI, Yamada N, Cheung KS, Tilley S, Clarke NM, Oreffo RO, Kokubun S, Bronner F. Association between the abnormal expression of matrix-degrading enzymes by human osteoarthritic chondrocytes and demethylation of specific CpG sites in the promoter regions. Arthritis Rheum 2005, 52:3110-3124. 10.1002/art.21300, 16200590.
6. Neuhold LA, Killar L, Zhao W, Sung ML, Warner L, Kulik J, Turner J, Wu W, Billinghurst C, Meijers T, Poole AR, Babij P, DeGennaro LJ. Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. J Clin Invest 2001, 107:35-44. 10.1172/JCI10564, 198546, 11134178.
7. Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma HL, Flannery CR, Peluso D, Kanki K, Yang Z, Majumdar MK, Morris EA. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005, 434:644-648. 10.1038/nature03369, 15800624.
8. Majumdar MK, Askew R, Schelling S, Stedman N, Blanchet T, Hopkins B, Morris EA, Glasson SS. Double-knockout of ADAMTS-4 and ADAMTS-5 in mice results in physiologically normal animals and prevents the progression of osteoarthritis. Arthritis Rheum 2007, 56:3670-3674. 10.1002/art.23027, 17968948.
9. Hunter DJ, Zhang YQ, Niu JB, Tu X, Amin S, Clancy M, Guermazi A, Grigorian M, Gale D, Felson DT. The association of meniscal pathologic changes with cartilage loss in symptomatic knee osteoarthritis. Arthritis Rheum 2006, 54:795-801. 10.1002/art.21724, 16508930.
10. Ding C, Martel-Pelletier J, Pelletier JP, Abram F, Raynauld JP, Cicuttini F, Jones G. Meniscal tear as an osteoarthritis risk factor in a largely non-osteoarthritic cohort: a cross-sectional study. J Rheumatol 2007, 34:776-784.
11. Clements KM, Price JS, Chambers MG, Visco DM, Poole AR, Mason RM. Gene deletion of either interleukin-1beta, interleukin-1beta-converting enzyme, inducible nitric oxide synthase, or stromelysin 1 accelerates the development of knee osteoarthritis in mice after surgical transection of the medial collateral ligament and partial medial meniscectomy. Arthritis Rheum 2003, 48:3452-3463. 10.1002/art.11355, 14673996.
12. Sampson ER, Beck CA, Ketz J, Canary KL, Hilton MJ, Awad H, Schwarz EM, Chen D, O'Keefe RJ, Rosier RN, Zuscik MJ. Establishment of an index with increased sensitivity for assessing murine arthritis. J Orthop Res 2011, 29:1145-1151. 10.1002/jor.21368, 3115505, 21374709.
13. Stickens D, Behonick DJ, Ortega N, Heyer B, Hartenstein B, Yu Y, Fosang AJ, Schorpp-Kistner M, Angel P, Werb Z. Altered endochondral bone development in matrix metalloproteinase 13-deficient mice. Development 2004, 131:5883-5895. 10.1242/dev.01461, 2771178, 15539485.
14. Chen M, Lichtler AC, Sheu TJ, Xie C, Zhang X, O'Keefe RJ, Chen D. Generation of a transgenic mouse model with chondrocyte-specific and tamoxifen-inducible expression of Cre recombinase. Genesis 2007, 45:44-50. 10.1002/dvg.20261, 2654410, 17211877.
15. Wang M, Jin H, Tang D, Huang S, Zuscik M, Chen D. Smad1 plays an essential role in bone development and postnatal bone formation. Osteoarthritis Cartilage 2011, 19:751-762. 10.1016/j.joca.2011.03.004, 3113680, 21420501.
16. Zhu M, Chen M, Lichtler AC, O'Keefe RJ, Chen D. Tamoxifen-inducible Cre-recombination in articular chondrocytes of adult Col2a1CreERT2 transgenic mice. Osteoarthritis Cartilage 2008, 16:129-130. 10.1016/j.joca.2007.08.001, 2271067, 17888690.
17. Chen JM, Nelson FC, Levin JI, Mobilio D, Moy FJ, Nilakantan R, Zask A, Powers R. Structure-based design of a novel, potent, and selective inhibitor for MMP-13 utilizing NMR spectroscopy and computer-aided molecular design. J Am Chem Soc 2000, 122:9648-9654.
18. Hernández Ríos M, Sorsa T, Obregón F, Tervahartiala T, Valenzuela MA, Pozo P, Dutzan N, Lesaffre E, Molas M, Gamonal J. Proteolytic roles of matrix metalloproteinase (MMP)-13 during progression of chronic periodontitis: initial evidence for MMP-13/MMP-9 activation cascade. J Clin Periodontol 2009, 36:1011-1017. 10.1111/j.1600-051X.2009.01488.x, 19929954.
19. Alcaraz MJ, Megías J, García-Arnandis I, Clérigues V, Guillén MI. New molecular targets for the treatment of osteoarthritis. Biochem Pharmacol 2010, 80:13-21. 10.1016/j.bcp.2010.02.017, 20206140.
20. Little CB, Barai A, Burkhardt D, Smith SM, Fosang AJ, Werb Z, Shah M, Thompson EW. Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development. Arthritis Rheum 2009, 60:3723-3733. 10.1002/art.25002, 2832925, 19950295.
21. Inada M, Wang Y, Byrne MH, Rahman MU, Miyaura C, López-Otín C, Krane SM. Critical roles for collagenase-3 (Mmp13) in development of growth plate cartilage and in endochondral ossification. Proc Natl Acad Sci USA 2004, 101:17192-17197. 10.1073/pnas.0407788101, 535367, 15563592.
22. Glasson SS, Askew R, Sheppard B, Carito BA, Blanchet T, Ma HL, Flannery CR, Kanki K, Wang E, Peluso D, Yang Z, Majumdar MK, Morris EA. Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice. Arthritis Rheum 2004, 50:2547-2558. 10.1002/art.20558, 15334469.
23. Blanco FJ, Guitian R, Vazquez-Martul E, de Toro FJ, Galdo F. Osteoarthritis chondrocytes die by apoptosis. A possible pathway for osteoarthritis pathology. Arthritis Rheum 1998, 41:284-289. 10.1002/1529-0131(199802)41:2<284::AID-ART12>3.0.CO;2-T, 9485086.
24. Thomas CM, Fuller CJ, Whittles CE, Sharif M. Chondrocyte death by apoptosis is associated with cartilage matrix degradation. Osteoarthritis Cartilage 2007, 15:27-34. 10.1016/j.joca.2006.06.012, 16859932.
25. Sharif M, Whitehouse A, Sharman P, Perry M, Adams M. Increased apoptosis in human osteoarthritic cartilage corresponds to reduced cell density and expression of caspase-3. Arthritis Rheum 2004, 50:507-515. 10.1002/art.20020, 14872493.
26. Peterson JT. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc Res 2006, 69:677-687. 10.1016/j.cardiores.2005.11.032, 16413004.
27. Peterson JT. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev 2004, 9:63-79.
28. Baragi VM, Becher G, Bendele AM, Biesinger R, Bluhm H, Boer J, Deng H, Dodd R, Essers M, Feuerstein T, Gallagher BM, Gege C, Hochgürtel M, Hofmann M, Jaworski A, Jin L, Kiely A, Korniski B, Kroth H, Nix D, Nolte B, Piecha D, Powers TS, Richter F, Schneider M, Steeneck C, Sucholeiki I, Taveras A, Timmermann A, Van Veldhuizen J, Weik J, Wu X, Xia B. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheum 2009, 60:2008-2018. 10.1002/art.24629, 19565489.